#21

paper number

REQUEST FOR ACCESS

Date: 2-13-96

Serial Number: 599.543

Filing Date: 10-18-90

Applicants: Oppermann

Sir.

Request is hereby respectfully made for access to the file history of the following abandoned application referred to in U.S. patent number 5.266.683 or printed application number _____.

Respectfully submitted.

Chu Bezark

OFFICIAL USE ONLY

PROCESSED BY

FEB 13 1996

FIU

initials

FILE INFORMATION UNIT

US005266683A

United States Patent [19]

Oppermann et al.

[11] Patent Number: 5,266,683

[45] Date of Patent: * Nov. 30, 1993

[54] OSTEOGENIC PROTEINS

[75] Inventors: Hermann Oppermann, Medway; Engin Ozkaynak, Milford; Thangavel Kuberasampath, Medway; David C. Rueger, Hopkinton; Roy H. L. Pang, Medway, all of Mass.

[73] Assignee: Stryker Corporation, Kalamazoo, Mich.

[*] Notice: The portion of the term of this patent subsequent to Nov. 2, 2010 has been disclaimed.

[21] Appl. No.: 861,646

[22] Filed: Feb. 21, 1992

Related U.S. Application Data

[60] Continuation-in-part of Ser. No. 827,052, Jan. 28, 1992, Pat. No. 5,250,302, Ser. No. 579,865, Oct. 7, 1990, Pat. No. 5,108,753, Ser. No. 621,849, Dec. 4, 1990, abandoned, Ser. No. 621,988, Dec. 4, 1990, abandoned, Ser. No. 810,560, Dec. 20, 1991, abandoned, Ser. No. 569,920, Aug. 20, 1990, abandoned, Ser. No. 600,024, Oct. 18, 1990, abandoned, Ser. No. 599,543, Oct. 18, 1990, abandoned, Ser. No. 616,374, Nov. 21, 1990, Pat. No. 5,162,114, and Ser. No. 483,913, Feb. 22, 1990, Pat. No. 5,171,374, said Ser. No. 827,052, is a division of Ser. No. 179,406, Apr. 8, 1988, Pat. No. 4,968,590, said Ser. No. 579,865, is a division of Ser. No. 179,406, Apr. 8, 1988, said Ser. No. 621,849, is a division of Ser. No. 232,630, Aug. 15, 1988, abandoned, which is a continuation-in-part of Ser. No. 179,406, Aug. 15, 1988, said Ser. No. 621,988, is a division of Ser. No. 315,342, Feb. 23, 1989, Pat. No. 5,011,691, which is a continuation-in-part of Ser. No. 232,630, Feb. 23, 1989, said Ser. No. 810,560, is a continuation of Ser. No. 660,162, Feb. 22, 1991, abandoned, which is a continuation of Ser. No. 422,699, Oct. 17, 1989, abandoned, which is a continuation-in-part of Ser. No. 315,342, Oct. 17, 1989, said Ser. No. 569,920, is a continuation-in-part of Ser. No. 422,699, Oct. 17, 1989, and Ser. No. 483,913, Oct. 17, 1989, which is a continuation-in-part of Ser. No. 422,613, Oct. 17, 1989, Pat. No. 4,975,526, which is a continuation-in-part of Ser. No. 315,342, Oct. 17, 1989, said Ser. No. 600,024, is a continuation-in-part of Ser. No. 569,920, Oct. 17, 1989, said Ser. No. 599,543, is a continuation-in-part of Ser. No. 569,920, Oct. 17, 1989.

[51] Int. Cl.[5] A61K 37/02; C07K 5/00; C07K 7/00; C07K 15/00

[52] U.S. Cl. 530/326; 530/327; 530/328; 530/350; 530/395; 530/840

[58] Field of Search 530/326, 327, 328, 395, 530/840, 300, 350

[56] References Cited

U.S. PATENT DOCUMENTS

4,172,128	10/1979	Thiele et al.	424/95
4,294,753	10/1981	Urist	530/356
4,394,372	7/1983	Jefferies	424/15
4,434,094	2/1984	Seyedin et al.	530/356
4,455,256	6/1984	Urist	530/356
4,563,350	1/1986	Nathan et al.	424/95
4,563,489	1/1986	Urist	524/21

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

069260 6/1982 European Pat. Off. .

(List continued on next page.)

OTHER PUBLICATIONS

Canalis et al., Science 210:1021-1023 (1980).
Glowacki et al., Lancet 1:959-963 (1981).
Reddi, Collagen Rel. Res. 1:209-226 (1981).
Sampath et al. Proc. Natl. Acad. Sci. USA 78:7599-7603 (1981).

(List continued on next page.)

Primary Examiner—Nathan M. Nutter
Attorney, Agent, or Firm—Testa, Hurwitz & Thibeault

[57] ABSTRACT

Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.

58 Claims, 47 Drawing Sheets